PubRank
Search
About
Daniel Petrylak
Author PubWeight™ 34.67
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
J Clin Oncol
2008
18.54
2
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Lancet Oncol
2013
3.45
3
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
J Clin Oncol
2004
2.04
4
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Cancer Immunol Immunother
2012
1.82
5
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed.
BJU Int
2007
1.72
6
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
Cancer
2009
1.70
7
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
J Natl Cancer Inst
2013
1.27
8
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Clin Cancer Res
2007
1.23
9
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
J Clin Oncol
2002
0.98
10
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Cancer
2004
0.97
11
Castration-resistant prostate cancer: descriptive yet pejorative?
J Clin Oncol
2010
0.85
12
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
J Immunother
2007
0.84
13
Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
Cancer
2002
0.82
14
Successive therapies may extend survival in AIPC. Interview by Alice Goodman.
RN
2007
0.75